Health1 min read

STAT+: HHS plans funding for research into ibogaine for PTSD

By · Via STAT Health · Published by Everything Blog

In short

The Department of Health and Human Services intends to allocate funding specifically for research evaluating ibogaine as a therapeutic option for post-traumatic stress disorder. In the commercial sector, smart ring manufacturer Oura's acquisition of Counsel Health is creating potential entanglements for Eli Lilly. Lilly connects prospective GLP-1 patients directly to Counsel Health through its proprietary LillyDirect pharmacy platform. If an existing commitment to acquire fifty million dollars in Oura stock proceeds, the pharmaceutical giant could end up owning a financial interest in the provider it steers customers toward.

Key points

  • Federal agencies are increasingly evaluating ibogaine to address post-traumatic stress di…: Federal agencies are increasingly evaluating ibogaine to address post-traumatic stress disorder in clinical settings.
  • The Oura transaction could grant Eli Lilly an indirect financial interest in a telehealth…: The Oura transaction could grant Eli Lilly an indirect financial interest in a telehealth partner it actively promotes.
  • Eli Lilly has not yet fulfilled its commitment to purchase fifty million dollars of Oura…: Eli Lilly has not yet fulfilled its commitment to purchase fifty million dollars of Oura stock due to unmet conditions.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I’m plunging into psychedelia again — journalistically speaking. If you have any interesting tips on the matter, email me!

Oura deal may complicate Lilly’s GLP-1 telehealth ties

Eli Lilly already sends patients looking for a GLP-1 prescription to Counsel Health through its pharmacy platform LillyDirect. Now, smart ring maker Oura is buying Counsel, which could give Lilly a financial interest in a telehealth company it promotes. Lilly has agreed to buy $50 million in Oura stock if certain conditions are met, though the drugmaker says those conditions haven’t been met yet, STAT’s Elaine Chen writes.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health